|1.||Maynadier, Marie: 2 articles (11/2013 - 10/2013)|
|2.||Garcia, Marcel: 2 articles (11/2013 - 10/2013)|
|3.||Isidoro, Ciro: 2 articles (08/2012 - 02/2002)|
|4.||Nishio, Hikaru: 2 articles (01/2012 - 02/2006)|
|5.||Yamato, Masanori: 2 articles (01/2012 - 02/2006)|
|6.||Takeuchi, Koji: 2 articles (01/2012 - 02/2006)|
|7.||Nagahama, Kenji: 2 articles (01/2012 - 02/2006)|
|8.||Junaid, M A: 2 articles (04/2000 - 01/2000)|
|9.||Pullarkat, R K: 2 articles (04/2000 - 01/2000)|
|10.||Pan, Jiawei: 1 article (01/2016)|
|1.||Peptic Esophagitis (Reflux Esophagitis)
02/01/2006 - "In the present study, we examined the effect of pepstatin, a specific inhibitor of pepsin, on acid reflux esophagitis. "
02/01/2006 - "These results suggest that pepstatin is highly effective against acid reflux esophagitis, without influencing acid secretion, while L-glutamine aggravated these lesions by increasing the pepsin activity by shifting the intraluminal pH to the optimal pH range for proteolytic action. "
02/01/2006 - "Acid reflux esophagitis was induced in rats by ligating both the pylorus and the forestomach for 3 or 4 hr. Pepstatin, ecabet Na (the anti-ulcer drug), and L-glutamine were administered intragastrically after the ligation. "
|2.||Sarcoma (Soft Tissue Sarcoma)
|3.||Neuronal Ceroid-Lipofuscinoses (Neuronal Ceroid Lipofuscinosis)
04/01/2000 - "In the present study the activity of a newly discovered acidic lysosomal pepstatin-insensitive proteinase (CLN2p) was measured in breast tissues by the most sensitive and highly specific assay that we had developed for the diagnosis of late-infantile neuronal ceroid lipofuscinosis (LINCL) (2). "
04/02/1999 - "A recent study has shown mutations in CLN2 gene, that encodes a novel lysosomal pepstatin-insensitive proteinase (LPIP), in the pathophysiology of late-infantile neuronal ceroid lipofuscinosis (LINCL). "
07/01/2001 - "Diagnosis of late-infantile neuronal ceroid lipofuscinosis: a new sensitive method to assay lysosomal pepstatin-insensitive proteinase activity in human and animal specimens by capillary electrophoresis."
02/24/2000 - "Fibroblasts from classical late infantile neuronal ceroid lipofuscinosis patients have less than 5% of the normal tripeptidyl peptidase activity and pepstatin-insensitive endopeptidase activity. "
01/01/2000 - "A lysosomal pepstatin-insensitive proteinase (CLN2p) deficiency is the underlying defect in the classical late-infantile neuronal ceroid lipofuscinosis (LINCL, CLN2). "
10/28/2013 - "We showed that this pepstatin conjugate (JMV4463) exhibited high anti-proliferative effect on tumor cell cultures via intracellular CathD inhibition and altered cell cycle associated with apoptotic events in vitro. "
08/01/1995 - "The two cancer cell lines have approximately 1.5 to 2.0-fold increased total acid protease activity and 2 to 3-fold increased pepstatin-inhibitable protease activity (i.e. "
02/01/1991 - "Pepstatin inhibited 78 +/- 6% of the proteolytic activity in the tumor measured by 125I-labeled undenatured mouse albumin as the substrate. "
07/01/1979 - "In MM46, CCM and NTF tumor strains there was also a decrease in the tumor cell numbers following pepstatin treatment. "
07/01/1977 - "The effect of pepstatin on the kinetics of ascitic fluid accumulation in L1210 tumor-bearing mice (DBA/2) was observed. "
07/01/1979 - "The results confirm previous studies of pepstatin's ability to retard ascites in L1210 and P-815Y ascites tumors and also broaden the concept of the mechanisms by which petstatin may be acting."
07/01/1979 - "Kinetic studies on ascites accumulation with tumor strain MM46 demonstrated that even when pepstatin was injected after ascites accumulation it reduced the ascites volume. "
07/01/1979 - "Studies were done of the effect of pepstatin on ascites accumulation in mice bearing MM46, Ehrlich, CCM, SN36, L1210, and NTF ascites tumors. "
07/01/1979 - "Further studies of the effect of pepstatin on ascites accumulation in tumor-bearing mice."
07/01/1979 - "A dose-dependent effect was observed in this tumor strain when pepstatin was injected both before and after ascites accumulation. "
|1.||Pepsin A (Pepsin)
|6.||Virulence Factors (Pathogenicity Factors)
|7.||Aspartic Acid (Aspartate)
|9.||Peptide Hydrolases (Proteases)
|10.||Protease Inhibitors (Protease Inhibitor)